Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tusamitamab ravtansine plus ramucirumab in CEACAM5-positive advanced gastric or GEJ adenocarcinoma
2021-001967-26Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tusamitamab ravtansine in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Sanofi. Primary endpoint: Dose-limiting toxicities (DLTs). Started Jun 2021; status: completed.
02
Drugs
tusamitamab ravtansine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2021-001967-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001967-26.